TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
Study: NCT02951039

Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study: NCT03362138

Intervention type: DEVICE
Intervention: dermoscopy
Description: Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
Study: NCT00628095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224,535
Description: 500 mg po BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active ingredient
Study: NCT05362240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four corner fusion
Description: First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three corner fusion without triquetrum excision
Description: First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
Study: NCT02061683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Description: Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
Study: NCT03375515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA pump
Description: 1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs.
Study: NCT01658449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%
Description: Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalable Hypertonic saline 7%
Description: Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
Study: NCT00775554

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided hematoma block
Description: pt. will receive ultrasound guided hematoma block

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided hematoma block
Description: ultrasound will be used to guide hematoma blocks
Study: NCT02235441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
Study: NCT00822575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZapperClick
Description: The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ZapperClick
Description: The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
Study: NCT04030260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and PD-1 antibody in Combination with Radiotherapy
Description: Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy is believed to increase the likelihood of response of immunotherapy
Study: NCT02490748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study: NCT00322361

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified process Hepatitis B Vaccine
Description: Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
Study: NCT02596217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection (stage 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion (stage 2)
Study: NCT01414543

Intervention type: OTHER
Group type: OTHER
Intervention: Information Sheet
Description: Providing the Participant with information regarding the aim of the experiment

Intervention type: OTHER
Group type: OTHER
Intervention: Consent
Description: Providing a consent form for participants. The participant is aware of his or her rights

Intervention type: OTHER
Group type: OTHER
Intervention: interview
Description: participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence

Intervention type: OTHER
Group type: OTHER
Intervention: Debrief
Description: at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
Study: NCT00598117

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS
Study: NCT00571571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy with parent collateral/psychoeducation as necessary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Individual psychotherapy and family interventions (as needed)
Study: NCT02515994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon C
Description: Investigational contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Marketed Monthly Replacement Lens (Control)
Study: NCT01634659

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses (DAILIES TOTAL1®)
Description: Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses (DAILIES TOTAL1®)
Description: Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)
Description: Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)
Description: Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
Study: NCT02703506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session of Pain Education programe
Description: Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
Study: NCT00140530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (Taxus)
Description: patients has been implanted the Paclitaxel-eluting stent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stent
Description: patients has been implanted the Rapamycin-eluting stent.
Study: NCT04295343

Intervention type: DIAGNOSTIC_TEST
Intervention: Three-dimensional (3D) rectal water contrast transvaginal ultrasonography
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed colonography
Description: Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
Study: NCT02057913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
Study: NCT03782974

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beta glucan
Description: Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta glucan
Description: Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Study: NCT02618694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic adrenalectomy
Description: Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic adrenalectomy
Description: On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
Study: NCT02621658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear Liquid Diet
Description: Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Liquid Diet
Description: Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
Study: NCT02071602

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD-NP
Description: Randomized 1:1:1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: Randomized 1:1:1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD-NP
Description: Randomized 1:1:1
Study: NCT02033200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stendra 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stendra 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03197870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Description: Subcutaneous AKB-9778 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Description: Subcutaneous AKB-9778 15mg
Study: NCT00820820

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROUVAX
Description: Measles vaccine (ROUVAX ®), Schwarz strain (\>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Vehicle (water for injection), 0.5 ml, once
Study: NCT03197870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Placebo
Study: NCT01432275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator blood glucose meter
Description: Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator blood glucose meter
Description: Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter with insulin calculator active
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator activated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter with insulin calculator active
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
Study: NCT04601584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 4, GNR-084
Description: 4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 5, GNR-084
Description: 10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 6, GNR-084
Description: 20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study: NCT00040378

Intervention type: DRUG
Intervention: alphatocopherol
Description: 400 IU daily

Intervention type: DRUG
Intervention: alphatocopherol
Description: 400 IU daily

Intervention type: DRUG
Intervention: Selenium
Description: 200mcg daily

Intervention type: DRUG
Intervention: Selenium
Description: 200mcg daily

Intervention type: DRUG
Intervention: Placebo replacement for vitamin E
Description: 1 placebo pill daily

Intervention type: DRUG
Intervention: Placebo replacement for vitamin E
Description: 1 placebo pill daily

Intervention type: DRUG
Intervention: Placebo replacement for Selenium
Description: 1 placebo pill daily

Intervention type: DRUG
Intervention: Placebo replacement for Selenium
Description: 1 placebo pill daily
Study: NCT01805609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working with the Caregiving Family (WCF) training
Description: Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
Study: NCT00504959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab